Trial · NCT07899996
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part I(Phase Ib): AEs | From baseline to week 16 | Incidence of participants with adverse events |
| Primary | Part I (Phase Ib): Tss_max | From baseline to week 16 | The time required to reach the maximum concentration of HB0056 in the bloodstream after administration at steady state. |
| Primary | Part II (Phase II): Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) | From baseline to week 12 | |
| Secondary | Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at each evaluation time | Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks | |
| Secondary | Change from baseline in Fractional exhaled nitric oxide(FeNO) at each evaluation time | Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks | |
| Secondary | Change from baseline in forced vital capacity(FVC) at each evaluation time | Part II (Phase II): 52 weeks | |
| Secondary | Change from baseline in The Forced Expiratory Flow 25-75% (FEF 25-75%) at each evaluation time | Part II (Phase II): 52 weeks | |
| Secondary | Change from baseline in peak expiratory flow (PEF) at each evaluation time | Part I(Phase Ib): 16 weeks | |
| Secondary | Change from baseline in Asthma Control Questionnaire( ACQ-6) at each evaluation time | Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks | |
| Secondary | Annualized rate of the severe asthma exacerbation event | Part II (Phase II): 52 weeks | |
| Secondary | Time to the first onset of the severe asthma exacerbation event | Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks | |
| Secondary | Change from baseline in the Standardized Asthma Quality of Life Questionnaire (AQLQ(S)) score at each evaluation time point | Part II (Phase II): 52 weeks | |
| Secondary | Incidence of Adverse events (AEs) | Part II (Phase II): 56 weeks | |
| Secondary | Incidence of anti-drug antibodies (ADAs) | Part I(Phase Ib): 16 weeksPart II (Phase II): 56 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07899996/registered